285 related articles for article (PubMed ID: 27396817)
1. B cells and antibodies in progressive multiple sclerosis: Contribution to neurodegeneration and progression.
Fraussen J; de Bock L; Somers V
Autoimmun Rev; 2016 Sep; 15(9):896-9. PubMed ID: 27396817
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis.
Lassmann H
Front Immunol; 2018; 9():3116. PubMed ID: 30687321
[TBL] [Abstract][Full Text] [Related]
3. Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice.
Cristofanilli M; Rosenthal H; Cymring B; Gratch D; Pagano B; Xie B; Sadiq SA
Exp Neurol; 2014 Nov; 261():620-32. PubMed ID: 25111532
[TBL] [Abstract][Full Text] [Related]
4. The pathogenesis of primary progressive multiple sclerosis: antibody-mediated attack and no repair?
Pender MP
J Clin Neurosci; 2004 Sep; 11(7):689-92. PubMed ID: 15337125
[TBL] [Abstract][Full Text] [Related]
5. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.
Magliozzi R; Howell O; Vora A; Serafini B; Nicholas R; Puopolo M; Reynolds R; Aloisi F
Brain; 2007 Apr; 130(Pt 4):1089-104. PubMed ID: 17438020
[TBL] [Abstract][Full Text] [Related]
6. Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index.
de Bock L; Fraussen J; Villar LM; Álvarez-Cermeño JC; Van Wijmeersch B; van Pesch V; Stinissen P; Somers V
Eur J Neurol; 2016 Apr; 23(4):722-8. PubMed ID: 26706657
[TBL] [Abstract][Full Text] [Related]
7. A new focal model resembling features of cortical pathology of the progressive forms of multiple sclerosis: Influence of innate immunity.
Silva BA; Leal MC; Farías MI; Avalos JC; Besada CH; Pitossi FJ; Ferrari CC
Brain Behav Immun; 2018 Mar; 69():515-531. PubMed ID: 29378262
[TBL] [Abstract][Full Text] [Related]
8. The relation between inflammation and neurodegeneration in multiple sclerosis brains.
Frischer JM; Bramow S; Dal-Bianco A; Lucchinetti CF; Rauschka H; Schmidbauer M; Laursen H; Sorensen PS; Lassmann H
Brain; 2009 May; 132(Pt 5):1175-89. PubMed ID: 19339255
[TBL] [Abstract][Full Text] [Related]
9. The pathology of primary progressive multiple sclerosis.
Lucchinetti C; Bruck W
Mult Scler; 2004 Jun; 10 Suppl 1():S23-30. PubMed ID: 15218806
[TBL] [Abstract][Full Text] [Related]
10. Immunological differences between classical phenothypes of multiple sclerosis.
Iwanowski P; Losy J
J Neurol Sci; 2015 Feb; 349(1-2):10-4. PubMed ID: 25586536
[TBL] [Abstract][Full Text] [Related]
11. Ectopic lymphoid follicles in progressive multiple sclerosis: From patients to animal models.
Zhan J; Kipp M; Han W; Kaddatz H
Immunology; 2021 Nov; 164(3):450-466. PubMed ID: 34293193
[TBL] [Abstract][Full Text] [Related]
12. [New therapeutic approaches in progressive multiple sclerosis].
Faissner S; Gold R
Fortschr Neurol Psychiatr; 2019 Nov; 87(11):653-671. PubMed ID: 31783427
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies against central nervous system antigens in a subset of B cell-dominant multiple sclerosis patients.
Kuerten S; Lanz TV; Lingampalli N; Lahey LJ; Kleinschnitz C; Mäurer M; Schroeter M; Braune S; Ziemssen T; Ho PP; Robinson WH; Steinman L
Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21512-21518. PubMed ID: 32817492
[TBL] [Abstract][Full Text] [Related]
14. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
[TBL] [Abstract][Full Text] [Related]
15. Role of B cells and antibodies in multiple sclerosis.
Wanleenuwat P; Iwanowski P
Mult Scler Relat Disord; 2019 Nov; 36():101416. PubMed ID: 31577986
[TBL] [Abstract][Full Text] [Related]
16. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis.
Farrokhi M; Saadatpour Z; Fadaee E; Saadatpour L; Rezaei A; Moeini P; Amani Beni A
Iran J Allergy Asthma Immunol; 2016 Dec; 15(6):536-546. PubMed ID: 28129686
[TBL] [Abstract][Full Text] [Related]
17. Intrathecal Inflammation in Progressive Multiple Sclerosis.
Monaco S; Nicholas R; Reynolds R; Magliozzi R
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153042
[TBL] [Abstract][Full Text] [Related]
18. Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis.
Baker D; Jacobs BM; Gnanapavan S; Schmierer K; Giovannoni G
Mult Scler Relat Disord; 2019 Oct; 35():19-25. PubMed ID: 31279232
[TBL] [Abstract][Full Text] [Related]
19. B cell rich meningeal inflammation associates with increased spinal cord pathology in multiple sclerosis.
Reali C; Magliozzi R; Roncaroli F; Nicholas R; Howell OW; Reynolds R
Brain Pathol; 2020 Jul; 30(4):779-793. PubMed ID: 32243032
[TBL] [Abstract][Full Text] [Related]
20. B cells and multiple sclerosis.
Franciotta D; Salvetti M; Lolli F; Serafini B; Aloisi F
Lancet Neurol; 2008 Sep; 7(9):852-8. PubMed ID: 18703007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
